Status: Recruiting
A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma
A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) Over a 12-Week Treatment Period in Patients With Severe Asthma Not Controlled With Medium to High Dose ICS/LABA
Participants needed: 512
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Kinaset Therapeutics IncUpdated: Jul 28, 2026Locations: 14
Eligibility criteria
Not listed